Educational portal offers modules, case studies, and other resources related to medical cannabis for medical professionals
Established with the support of pain management, neurology and dermatology experts, the portal is designed to address potential gaps in knowledge and training related to the potential use of cannabis in medical settings. It has been.
TORONTO, October 18, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a global, commercial-stage biopharmaceutical company focused on the commercialization of evidence-based cannabinoid-based products and medical cannabis. We are happy to announce that it is now available.Education Portal, “Avicenna Academy”, Free Resources and Medical Education Portal for Medical Professionals (“HCP”)). The Medical Education Portal is designed to support healthcare professionals through education and practical information about the potential use of medical cannabis, with the goal of expanding access and measuring patient outcomes.
Avicenna Academy https://avicenna-academy.teachable.com
The Avicenna Academy is designed to address potential gaps in understanding cannabinoid-based products while making available resources and information that can be a tool for the medical community. To that end, Avicanna’s medical team has combined its research and development expertise with cannabinoid formulations utilizing advanced drug delivery systems. Practical experience in delivering RHO PhytoTMs With medical cannabis products through established medical portals, pharmacies, and leading hospitals in the Canadian and international markets, Avicanna provides access to downloadable guides, online modules, and discussions with key thought leaders across a range of medical specialties. We were able to develop a variety of educational resources, such as Access.
The portal now contains a variety of resources, including HCP guidelines and supporting information on medical approval documents for Canadian patients.
The preliminary set of modules covers various topics such as:
- History of medical cannabis use
- endocannabinoid system
- Potential therapeutic target
- Current Evidence State
- Overview of Dosing and Titration
- Case studies and practical applications
Avicenna Academy aims to expand its offerings on the portal to reflect ongoing research in this field. Access to the Avicenna Academy is provided free of charge to HCPs to support the education and training they need. The company is actively working with the medical community to improve on this current initiative, working with Canadian and international key opinion leaders and subject matter experts to build indication-specific modules. I am also working on
Avicanna Inc. CEO Aras Azadian said:
About Avicanna
Avicanna is a commercial-stage, international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including R&D and clinical development, leading to the commercialization of over 30 products in various market segments.
Medical cannabis and wellness products: Marketed under the RHO Phyto™ brand, these medical and wellness products are pharmaceutical grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio includes a complete formulary of products including oral, sublingual, topical, and transdermal delivery, with preclinical data-backed dosing, enhanced absorption and stability studies. It is Formularies are marketed with consumer, patient and healthcare professional education and training.
Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of indication-specific, patent-pending drug candidates in various stages of clinical development and commercialization. did. These cannabinoid-based drug candidates seek to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first drug (Trunerox™) is in the drug registration stage in South America.
Click to watch Avicanna’s Corporate Video 2022
SOURCE Avicanna Co., Ltd.
stay connected
For more information about Avicanna, please visit www.avicanna.com, contact Ivana Maric at info@avicanna.com, or follow us on social media at: LinkedIn, twitter, Facebook Also Instagram.
If you are a healthcare professional and want to learn more about medical cannabis use, visit the Avicenna Academy.
We will post updates through our official videos. Youtube channel.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release is may be identified by the use of words such as “will”, “predict” and “believe”. , “intends”, “plans”, “forecasts”, “plans”, “estimates”, “outlooks” and other similar expressions. Forward-looking information contained in this news release includes, but is not limited to, statements regarding our future business operations, potential collaborations, management’s opinions or beliefs, and future business objectives. not. Although we believe that the expectations and assumptions upon which such forward-looking information is based are reasonable, we cannot give any assurance that the forward-looking information will prove to be correct. You should not place undue reliance on information. Actual results and deployment may differ materially from those envisioned in these statements. Forward-looking information is subject to various risks and uncertainties that could cause actual events or results to differ materially from those projected by the forward-looking information. Such risks and uncertainties include current and future market conditions, including the market price of our common stock, and the risk factors described in our Annual Information Form filed on March 31, 2022. including but not limited to. Available from SEDAR’s company profile at www.sedar.com. Statements in this news release are current as of the date of this release. We disclaim any intention or obligation to update any forward-looking information, whether as a result of new information, future events, results or otherwise, except as required by applicable securities laws.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7823816b-08dc-4012-8a50-4303fbd85291.
.
Comments
Post a Comment